Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vivesto AB ( (SE:VIVE) ) has issued an announcement.
Vivesto AB has engaged Liberi Group, a global life science consultancy, to help identify international partners for its Paccal Vet and Cantrixil programs. This collaboration aims to accelerate the development and commercialization of these drug candidates by leveraging Liberi Group’s expertise in securing high-quality partners. The partnership is expected to enhance Vivesto’s ability to achieve upcoming milestones and strengthen its market position in both veterinary and human oncology sectors.
More about Vivesto AB
Vivesto AB is a Swedish development company focused on offering new treatment options for hard-to-treat cancers with significant medical needs and market potential. Their portfolio includes Cantrixil, aimed at blood cancer, and Paccal Vet, a veterinary oncology program under evaluation for dogs with splenic hemangiosarcoma and cats with solid tumors. Vivesto’s shares are traded on Nasdaq Stockholm.
Average Trading Volume: 833,581
Technical Sentiment Signal: Sell
Current Market Cap: SEK70.16M
Find detailed analytics on VIVE stock on TipRanks’ Stock Analysis page.